Oversulfated heparin by-products induce thrombin generation in human plasmas through contact system activation

Clinical and Applied Thrombosis/Hemostasis

Volumn 16, Issue 3, 2010, Pages 244-250

  Qian, Yi ^a   Pan, Jing ^a   Zhou, Xiaodong ^a   Hourcade, Dennis E ^a   Liszewski, M Kathryn ^a   Atkinson, John P ^a   Lu, Hong ^a   Zhang, Lijuan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Contact system; Contaminated heparin; Kallikrein; Thrombin

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 9; FIBRINOGEN; HEPARIN; KALLIKREIN; PREKALLIKREIN; PROTHROMBIN; THROMBIN; THROMBOPLASTIN;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; FIBRIN CLOT; HUMAN; PLASMA; PRIORITY JOURNAL;

ANAPHYLAXIS; ANTICOAGULANTS; BLOOD COAGULATION; CHONDROITIN SULFATES; COAGULATION PROTEIN DISORDERS; DISEASE OUTBREAKS; DRUG CONTAMINATION; ENZYME ACTIVATION; FIBRINOGEN; HEPARIN; HUMANS; KALLIKREINS; PHOSPHATIDYLETHANOLAMINES; PREKALLIKREIN; PROTHROMBIN; SILICON DIOXIDE; THROMBIN;

EID: 77953639112     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029610362071     Document Type: Article

References (22)

1. Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med. 2008 ; 359 (25). 2674-2684.
2. Information on adverse event reports and heparin. http://www.fdagov/ Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm112669htm
3. Kishimoto TK, Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008 ; 358 (23). 2457-2467. (Pubitemid 351793019)
4. Ueno A., Oh-ishi S. Roles for the kallikrein-kinin system in inflammatory exudation and pain: lessons from studies on kininogen-deficient rats. J Pharmacol Sci. 2003 ; 93 (1). 1-20.
5. Colman RW Contact activation (kallikrein-kinin) pathway: multiple physiologic and pathophysiologic activities. In: Colman RW, ed. Hemostasis and Thrombosis. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 107-130.
6. Huber-Lang M., Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006 ; 12 (6). 682-687. Accessed on April 30, 2010.
7. Clark A., Weymann A., Hartman E., et al. Evidence for non-traditional activation of complement factor C3 during murine liver regeneration. Mol Immunol. 2008 ; 45 (11). 3125-3132.
8. Pan J., Qi Y., Zhou X., Lu H., Ramacciotti E., Zhang L. Chemically Oversulfated Glycosaminoglycans are Potent Modulators of Contact System Activation and Different Cell Signaling Pathways. J Biol Chem 2010 ; doi: 10.1074/jbc.M109.063735.
9. Jenny NS, Lundblad RL, Mann KG Thrombin. In: Colman RW, ed. Hemostasis and Thrombosis. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 193-213.
10. Pan J., Qian Y., Zhou X., et al. Oversulfated Chondroitin Sulfate is not the Sole Contaminant in Heparin. Nature Biotech 2010 ; 28: 203-207.
11. Stief TW Kallikrein activates prothrombin. Clin Appl Thromb Hemost. 2008 ; 14 (1). 97-98.
12. Colman RW, Clowes AW, George JN, Goldhaber SZ, Marder VJ Overview of hemostasis. In: Colman RW, ed. Hemostasis and Thrombosis. Philadelphia, PA: Lippincott Williams & Wilkins; 2006: 3-16.
13. Orfeo T., Brummel-Ziedins KE, Gissel M., Butenas S., Mann KG The nature of the stable blood clot procoagulant activities. J Biol Chem. 2008 ; 283 (15). 9776-9786.
14. Waaler BA Contact activation in the intrinsic blood clotting system; studies on a plasma product formed on contact with glass and similar surfaces. Scand J Clin Lab Invest. 1959 ; 11 (suppl 37). 1-133.
15. Asmis LM, Sulzer I., Furlan M., Lammle B. Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. Thromb Res. 2002 ; 105 (6). 463-470.
16. Duvall WL Antithrombotic therapy. Curr Mol Med. 2006 ; 6 (5). 603-619.
17. Mousa SA Role of current and emerging antithrombotics in thrombosis and cancer. Timely Top Med Cardiovasc Dis. 2006 ; 10: E19.
18. Bartnik M, Norhammar A, Ryden L. Hyperglycaemia and cardiovascular disease. J Intern Med. 2007 ;262(2): 145-156.
19. Grand'Maison A., Charest AF, Geerts WH Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs. 2005 ; 5 (5). 291-305.
20. Swigris JJ, Fischer A., Gillis J., Meehan RT, Brown KK Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest. 2008 ; 133 (1). 271-280.
21. Linkins LA, Warkentin TE The approach to heparin-induced thrombocytopenia. Semin Respir Crit Care Med. 2008 ; 29 (1). 66-74.
22. Mullins ES, Kombrinck KW, Talmage KE, et al. Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain. Blood. 2009 ; 113 (3). 696-704.